Choong ANG Vaccine Laboratory

072020 · KOSDAQ · Health Care · SMALL CAP

Provisional Q2 2026 results.

Choong ANG Vaccine Laboratory filed provisional (unaudited) separate results for Q2 2026: revenue of US$8.37M (−1.2% year on year), operating profit of US$804K (−23.8% year on year) and net income of US$907K (+90.4% year on year).

Earnings(Operating results (preliminary) (fair disclosure))· FILED 2026-08-05· RCEPT 20260805900274

US$8.37MRevenue
−1.2%Revenue vs a year earlier
US$804KOperating profit

Converted at 1 USD ≈ ₩1,421.16 (filing-date rate, 2026-08-05 close)

What happened

Choong ANG Vaccine Laboratory filed provisional (unaudited) separate results for Q2 2026: revenue of US$8.37M (−1.2% year on year), operating profit of US$804K (−23.8% year on year) and net income of US$907K (+90.4% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$8.37M
Revenue vs a year earlier−1.2%
Operating profitUS$804K
Net incomeUS$907K
PeriodQ2 2026 (separate)
Filed2026-08-05, Operating results (preliminary) (fair disclosure)
SourceDART rcept 20260805900274 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-08-05 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.